AR020306A1 - THERAPEUTIC COMPOSITION AND ITS USE AS AN INHIBITOR OF CICLOOXIGENASA-2 IN THE PREVENTION OF CARDIOVASCULAR ALTERATIONS. - Google Patents

THERAPEUTIC COMPOSITION AND ITS USE AS AN INHIBITOR OF CICLOOXIGENASA-2 IN THE PREVENTION OF CARDIOVASCULAR ALTERATIONS.

Info

Publication number
AR020306A1
AR020306A1 ARP980101789A AR020306A1 AR 020306 A1 AR020306 A1 AR 020306A1 AR P980101789 A ARP980101789 A AR P980101789A AR 020306 A1 AR020306 A1 AR 020306A1
Authority
AR
Argentina
Prior art keywords
heterocyclyl
alkyl
arylamino
inhibitor
unsaturated
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of AR020306A1 publication Critical patent/AR020306A1/en

Links

Abstract

La composicion terapéutica consiste en un inhibidor de ciclo-oxigenasa-2 o una sal farmacéuticamente aceptable o derivado del mismo y su uso para prevenirla afeccion cardiovascular relacionada con la inflamacion en un individuo que necesita taltrata miento, composicion que es seleccionada entre meloxicam,nimesulida, MK-966, L-783003, T-614, D-1367, L-748731, , CT3, CGP-28238, BF-389, GR-253035, ácido (E)-4-(1,3BIS(ciclohexilmetil)-1,2,3,6-tetrahidro-2,6-dioxo-9H-purin-8-il)cinámico, L-745337 y c ompuestos de formula 1: donde A es un sustituyente seleccionado a partir de anillos heterocíclicos parcialmente insaturadoso insaturados y carbocíclicos parcialmente insaturados o insaturados; donde R1 es como mínimo un sustituyenteseleccionado a pa rtir de heterociclo,cicloalquilo, cicloalquenilo y arilo, donde R1 es opcionalmente sustituido en una posicion sustituible con uno o más radicales seleccionados entre alquilohaloalquilo, ciano, carboxilo, alcoxicarbonilo,hidroxilo, hidroxialquilo, h aloalcoxi, amino, alquilamino, arilamino, nitro, alcoxialquilo, alquilsulfinilo,halo, alcoxi y alquiltio, donde R2 es metilo o amino; y donde R3 es un radical seleccionado a partir de hidruro, halo, alquilo, alquenilo,alquinilo, oxo,ciano, carboxilo , cianoalquilo, heterocicliloxi, alquiloxi, alquiltio, alquilcarbonilo, cicloalquilo, arilo, haloalquilo, heterociclilo cicloalquenilo,aralquilo, heterociclilalquilo, acilo, alquiltioalquilo, hidroxialquilo,alcoxicarbonilo, arilcarbonilo, aralquilca rbonilo, aralquenilo, alcoxialquilo,ariltioalquilo, ariloxialquilo, aralquiltioalquilo, aralcoxialquilo, aralcoxialquilo, alcoxiaralcoxialquilo, alcoxicarbonilalquilo, aminocarbonilo,aminocarbonilalquilo,alquilaminocarbonilo, N-arilaminocarbonilo, N -alquil-N-arilaminocarbonilo, alquilaminocarbonilalquilo, carboxialquilo, alquilamino,N-arilamino, N-aralquilamino, N-alquil-N-aralquilamino, Nalquil-N-arilamino, aminoalquilo, alquilaminoalquilo, N-arilaminoalquilo, N-aralquilaminoalquilo,N-alquil-N -aralquilaminoalquilo, N-alquil-N-arilaminoalquilo, ariloxi, aralcoxi, ariltio, aralquiltio, alquilsulfinilo, alquilsulfonilo, aminosulfonilo,The therapeutic composition consists of a cyclo-oxygenase-2 inhibitor or a pharmaceutically acceptable salt or derivative thereof and its use to prevent cardiovascular disease related to inflammation in an individual in need of taltering, composition that is selected from meloxicam, nimesulide, MK-966, L-783003, T-614, D-1367, L-748731,, CT3, CGP-28238, BF-389, GR-253035, acid (E) -4- (1,3BIS (cyclohexylmethyl) - 1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl) cinnamic, L-745337 and c formula 2: where A is a substituent selected from partially unsaturated heterocyclic rings unsaturated and partially unsaturated or unsaturated carbocyclics; where R1 is at least one substituent selected from heterocycle, cycloalkyl, cycloalkenyl and aryl, where R1 is optionally substituted in a substitutable position with one or more radicals selected from alkylhaloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, h aloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio, where R2 is methyl or amino; and where R3 is a radical selected from hydride, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl cycloalkenyl, aralkyl, heterocyclyl, heterocyclyl, heterocyclyl, heterocyclyl , alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, rbonilo aralquilca, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, Nalkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl- N-arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminos ulfonil,

ARP980101789 1997-05-16 1998-04-17 THERAPEUTIC COMPOSITION AND ITS USE AS AN INHIBITOR OF CICLOOXIGENASA-2 IN THE PREVENTION OF CARDIOVASCULAR ALTERATIONS. AR020306A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4662697P 1997-05-16 1997-05-16

Publications (1)

Publication Number Publication Date
AR020306A1 true AR020306A1 (en) 2002-05-08

Family

ID=45571889

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101789 AR020306A1 (en) 1997-05-16 1998-04-17 THERAPEUTIC COMPOSITION AND ITS USE AS AN INHIBITOR OF CICLOOXIGENASA-2 IN THE PREVENTION OF CARDIOVASCULAR ALTERATIONS.

Country Status (1)

Country Link
AR (1) AR020306A1 (en)

Similar Documents

Publication Publication Date Title
CU23116A3 (en) DERIVATIVES OF REPLACED BENCENSULFONAMIDE, AS COX-2 INHIBITORS
NZ509755A (en) Method of using benzenesulphoamides that are cyclooxygenase-2-inhibitors in the treatment and prevention of neoplasia
AU2250097A (en) Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist
AU745797B2 (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
ES2262156T3 (en) COMPOSITION THAT INCLUDES AN INHIBITOR OF CYCLOOXIGENASA 2 AND AN INHIBITOR OF LEUCOTRENE A4 HIDROLASA.
EP1397145B1 (en) Use of cox-2 inhibitors for the treatment of schizophrenia, or tic disorders
JP2004526765A5 (en)
US20020107276A1 (en) Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist
RU99110192A (en) METHOD OF USE OF CYCLOXYGENASE-2 INHIBITORS FOR TREATMENT AND PREVENTION OF NEOPLASION
EP1526869A1 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
JP2005501843A5 (en)
JP2006521353A (en) Composition of cyclooxygenase-2 selective inhibitor and 5-HT1B / 1D agonist for treatment and prevention of migraine
RU2004121147A (en) APPLICATION OF SOX-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS FOR TREATMENT OF INFECTION OF PAPILLOMA VIRUS
JP2005501850A5 (en)
WO2004060366A1 (en) A method for the treatment, prevention, or inhibition of a cns disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20020035156A1 (en) Combination therapy in the prevention of cardiovascular disorders
AR020306A1 (en) THERAPEUTIC COMPOSITION AND ITS USE AS AN INHIBITOR OF CICLOOXIGENASA-2 IN THE PREVENTION OF CARDIOVASCULAR ALTERATIONS.
US20070072861A1 (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
AR038199A1 (en) COMBINED THERAPY FOR THE TREATMENT OF BACTERIAL INFECTIONS
US20040022789A1 (en) Methods and compositions for treating T cell mediated inflammatory/autoimmune diseases and disorders in subjects having a glucocorticoid regulation deficiency
JP2001521889A5 (en)
AR014000A1 (en) METHOD FOR USING CYCLOOXYGENASE-2 INHIBITORS IN THE MAINTENANCE OF FETAL DUCTUS ATERIOSUS DURING TREATMENT AND PREVENTION OF WORK PREMATURE WORK
JP2007522084A (en) Treatment of migraine with nausea
JP2005535657A5 (en)
MXPA99009495A (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders

Legal Events

Date Code Title Description
FB Suspension of granting procedure